TOPAMAX 200MG 200 MG
TOPIRAMATE : 200 MG · DIN 02230896 · JANSSEN INC
Health Canada status: CANCELLED POST MARKET
What is TOPAMAX 200MG?
TOPAMAX 200MG 200 MG contains TOPIRAMATE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02230896, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 24-Jul-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TOPAMAX 200MG used for?
Monotherapy (6+ yrs) or adjunctive therapy (2+ yrs) for epilepsy. Prophylaxis of migraine headache in adults. Not for acute migraine treatment.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02230896 |
|---|---|
| Brand name | TOPAMAX 200MG |
| Generic / active ingredient | TOPIRAMATE : 200 MG |
| Manufacturer | JANSSEN INC |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AX11 TOPIRAMATE |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 24-Jul-2026 |
| Original market date | 1997-03-25 00:00:00 |
How is it administered?
Epilepsy: Titrate to 100-400 mg/day. Migraine: Titrate to 100 mg/day. Administered in two divided doses. Tablets should not be broken. Sprinkles can be added to soft food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (standard storage usually 15-30°C).
How is it supplied?
Tablets: Bottles of 60 or 100 with desiccant. Sprinkle Capsules: Bottles of 60.
Contraindications
Hypersensitivity to ingredients. Migraine prophylaxis is contraindicated in pregnancy and women of childbearing potential not using highly effective contraception.
Warnings and precautions
Withdraw gradually to avoid seizures. Risk of metabolic acidosis, hyperammonemia, encephalopathy, visual disturbances (secondary angle closure glaucoma), and suicidal ideation.
Is TOPIRAMATE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N03AX11 TOPIRAMATE. 42 of 125 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-TOPIRAMATE TABLETS | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02536730 |
| AG-TOPIRAMATE TABLETS | 25 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02536722 |
| APO-TOPIRAMATE | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02279630 |
| APO-TOPIRAMATE | 200 MG | TABLET | APOTEX INC | MARKETED | DIN 02279649 |
| APO-TOPIRAMATE | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 02279614 |
| AURO-TOPIRAMATE | 100 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02345838 |
| AURO-TOPIRAMATE | 200 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02345846 |
| AURO-TOPIRAMATE | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02345803 |
| GLN-TOPIRAMATE | 100 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | DIN 02287773 |
| GLN-TOPIRAMATE | 200 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | DIN 02287781 |
Who else supplies TOPIRAMATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TOPIRAMATE appears in 443 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.